For IHC3+ tumours, chemotherapy plus dual anti-HER2 therapy showed higher pCR rate than chemotherapy plus single anti-HER2 therapy (59.3% versus 50.0%; p = 0.41). The gene discussed is ERBB2; the disease is neoplasm.